Philip Ashton-Rickardt, originally from a working-class background in the UK, has built a notable career in biotechnology after transitioning from academia. He founded Smith Therapeutics in 2017, specializing in CAR-Treg therapies, which was acquired in 2019. Currently, he serves as Managing Director and Chief Scientific Officer at BE Therapeutics, focusing on proto-cortex implants for stroke and brain injuries. Ashton-Rickardt emphasizes the importance of resilience, continuous learning, and authenticity in entrepreneurship. His extensive experience includes tenure at prominent institutions and leadership roles in biotech companies.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.wboc.com/online_features/press_releases/always-learn-philip-ashton-rickardt-on-building-a-biotech-career-without-a-blueprint/article_f483d5b7-baf6-56e6-92d1-515b899e19e3.html
